OBJECTIVE: To determine effectiveness and safety of the combination of artesunate, sulphadoxine + pyrimethamine and primaquine in the treatment of P falciparum malaria. DESIGN: A hospital based prospective study. SETTING: Base Hospital, Moneragala. METHODS: In 30 P falciparum infected patients admitted to the hospital, blood was taken for estimation of haemoglobin, white cell counts, and serum levels of aspartate aminotransferase, alanine aminotransferase, bilirubin and creatinine. They were administered artesunate, sulphadoxine + pyrimethamine (S + P) and primaquine on day 0 (artesunate 4 mg/kg, sulphadoxine 25 mg/kg, pyrimethamine 1.25 mg/kg and primaquine 0.75 mg/kg), and only artesunate on days 1 and 2 (artesunate 4 mg/kg each day). Blood was examined for malarial parasites, and patients were assessed on days 1, 2, 7, 14, 21 and 28. Patients assessed the severity of selected symptoms. Biochemical analyses were done on day 0 and repeated on days 7 and 28. RESULTS: Eight patients presented with fever which resolved in 7 patients in 48 hours. Asexual parasites were cleared in 80% of the 30 patients within 24 hours of treatment and in all 30 by day 7. Gametocytaemia cleared in all patients by day 14. There were no adverse effects experienced by the patients. The white cell and differential counts, liver enzymes and creatinine levels were within normal limits on all follow up days. CONCLUSIONS: The combination of artesunate, S + P and primaquine was found to be effective and safe in the treatment of uncomplicated P falciparum malaria.
OBJECTIVE: To determine effectiveness and safety of the combination of artesunate, sulphadoxine + pyrimethamine and primaquine in the treatment of P falciparum malaria. DESIGN: A hospital based prospective study. SETTING: Base Hospital, Moneragala. METHODS: In 30 P falciparum infectedpatients admitted to the hospital, blood was taken for estimation of haemoglobin, white cell counts, and serum levels of aspartate aminotransferase, alanine aminotransferase, bilirubin and creatinine. They were administered artesunate, sulphadoxine + pyrimethamine (S + P) and primaquine on day 0 (artesunate 4 mg/kg, sulphadoxine 25 mg/kg, pyrimethamine 1.25 mg/kg and primaquine 0.75 mg/kg), and only artesunate on days 1 and 2 (artesunate 4 mg/kg each day). Blood was examined for malarial parasites, and patients were assessed on days 1, 2, 7, 14, 21 and 28. Patients assessed the severity of selected symptoms. Biochemical analyses were done on day 0 and repeated on days 7 and 28. RESULTS: Eight patients presented with fever which resolved in 7 patients in 48 hours. Asexual parasites were cleared in 80% of the 30 patients within 24 hours of treatment and in all 30 by day 7. Gametocytaemia cleared in all patients by day 14. There were no adverse effects experienced by the patients. The white cell and differential counts, liver enzymes and creatinine levels were within normal limits on all follow up days. CONCLUSIONS: The combination of artesunate, S + P and primaquine was found to be effective and safe in the treatment of uncomplicated P falciparum malaria.
Authors: Seif A Shekalaghe; Roel ter Braak; Modibo Daou; Reginald Kavishe; Wouter van den Bijllaardt; Sven van den Bosch; Jan B Koenderink; Adrian J F Luty; Christopher J M Whitty; Chris Drakeley; Robert W Sauerwein; Teun Bousema Journal: Antimicrob Agents Chemother Date: 2010-03-01 Impact factor: 5.191
Authors: Dolie D Laishram; Patrick L Sutton; Nutan Nanda; Vijay L Sharma; Ranbir C Sobti; Jane M Carlton; Hema Joshi Journal: Malar J Date: 2012-01-31 Impact factor: 2.979
Authors: Marcelo Gomes Davanço; Anna Caroline Campos Aguiar; Leandro Alves Dos Santos; Elias Carvalho Padilha; Michel Leandro Campos; Cleverton Roberto de Andrade; Luiz Marcos da Fonseca; Jean Leandro Dos Santos; Chung Man Chin; Antoniana Ursine Krettli; Rosangela Gonçalves Peccinini Journal: PLoS One Date: 2014-08-18 Impact factor: 3.240
Authors: Seif Shekalaghe; Chris Drakeley; Roly Gosling; Arnold Ndaro; Monique van Meegeren; Anders Enevold; Michael Alifrangis; Frank Mosha; Robert Sauerwein; Teun Bousema Journal: PLoS One Date: 2007-10-10 Impact factor: 3.240